Investor relations · First institutional round
Built without a rupee of outside capital.
Now raising to scale.
Since 2014 Truevet has run on export revenue alone — no venture money, no outside equity. The product and the export channel are proven; what has capped growth is people, labs and regulatory depth. This round funds exactly that, and takes a proven playbook into more markets, faster.
Live traction
01 · The ask
₹15–25 Cr. Staged equity.
Our first institutional round, raised in two tranches. The thesis is simple: twelve years of self-funded export sales have proven the products and the distributor model; a real science, regulatory and commercial team turns that into scale.
- Impact seed₹6–8 Cr
Open now
Builds the team, the Srinagar lab and a regulatory-affairs function; opens the next registered markets.
- Series A₹10–15 Cr
On milestones
Completes the Himalayan Phytogenics Research Centre and pilot extraction, and scales the distributor network.
The target is ₹100 Cr+ in revenue within five years of the round closing. Impact capital, non-dilutive research funding and strategic partners are all welcome alongside equity.
- 30%Team — science, regulatory affairs, commercialFormulation scientists, a dossier and registration team for new markets, and the partnership team that scales the distributor network.
- 30%Labs & the Himalayan Phytogenics Research CentreAnalytical and in-vitro screening capability in Srinagar, built on cultivated Kashmir botanicals and horticulture by-product feedstocks.
- 25%Working capital & inventoryExport order book, raw-material depth and distributor onboarding across new markets.
- 15%Market development & registrationsIn-market product registrations, trials with partners, distributor enablement and demand generation.
02 · Financial projections
To ₹110 Cr in five years.
Five-year model from the close of the round. The capital funds the inflection: EBITDA turns positive in year three, net profit in year four, and gross margin lifts as volume and in-house capability scale — the operating leverage on the right of the curve.
Historical financials — audited statements for the last three financial years — are shared with qualified investors on request, together with the full model assumptions, in the data room.
| Year | Revenue | Gross profit | EBITDA | PAT |
|---|---|---|---|---|
| Y1 | 7 | 3.5 | -1.3 | -1.4 |
| Y2 | 15 | 8.4 | -1.4 | -4.2 |
| Y3 | 30 | 17.4 | 0.3 | -3 |
| Y4 | 58 | 34.8 | 12.5 | 6.3 |
| Y5 | 110 | 68.2 | 40.2 | 25.9 |
All amounts in INR Crore · Y1 = first full financial year after the round closes · Illustrative model — full workings in the data room
03 · Vision
The five-year exit path.
Truevet's ambition is to be the reference brand for antibiotic-free animal-health across the markets where the shift is happening fastest — South & Southeast Asia, the Middle East and Africa. The regulatory direction is fixed, the incumbents at the top are consolidated and slow, and the mid-market we serve is structurally underserved.
A credible exit — strategic acquisition by a global animal-health major, or a public listing — is a five-to-seven-year horizon. What gets us there is capital deployed now, into capacity and reach, while the window is open.
04 · Leadership
Three people. One thesis.
Founder & CEO
BVSc · 10+ years in animal health
Co-founder & COO
PhD — Manufacturing & Quality · 15+ years in operations
Chief Scientific Officer
PhD — IIT Bombay · PDF — University of Texas (Green Chemistry)
Request the materials
Ten years of evidence.
One conversation away.
The investor deck, financial model, audited financials and data room are shared with qualified investors on request. Tell us who you are and we'll be in touch.
Prefer email? Write to ir@truevet.bio.